- Home
- CYTK
as 06-20-2025 4:00pm EST
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
| Founded: | 1997 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 5.6B | IPO Year: | 2004 |
| Target Price: | $70.92 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $29.31 - $61.38 | Next Earning Date: | 08-07-2025 |
| Revenue: | $19,218,000 | Revenue Growth: | 412.21% |
| Revenue Growth (this year): | 18.02% | Revenue Growth (next year): | 737.32% |
Stock Insider Trading Activity of Cytokinetics Incorporated (CYTK)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Malik Fady Ibraham | CYTK | EVP Research & Development | Jun 17 '25 | Sell | $32.91 | 2,000 | $65,820.00 | 140,610 | |
| Blum Robert I | CYTK | President & CEO | Jun 16 '25 | Sell | $33.80 | 5,000 | $169,000.00 | 403,108 | |
| Kaye Edward M. MD | CYTK | Director | Jun 5 '25 | Sell | $32.10 | 3,636 | $116,715.60 | 29,658 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | Jun 3 '25 | Sell | $31.88 | 2,000 | $63,760.00 | 140,610 | |
| Blum Robert I | CYTK | President & CEO | Jun 2 '25 | Sell | $31.22 | 5,000 | $156,100.00 | 403,108 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | May 20 '25 | Sell | $31.98 | 2,000 | $63,960.00 | 140,610 | |
| Blum Robert I | CYTK | President & CEO | May 16 '25 | Sell | $30.93 | 5,000 | $154,650.00 | 403,108 | |
| Bhanji Muna | CYTK | Director | May 15 '25 | Sell | $29.73 | 1,454 | $43,227.42 | 23,510 | |
| Malik Fady Ibraham | CYTK | EVP Research & Development | May 6 '25 | Sell | $35.01 | 2,000 | $70,020.00 | 140,610 | |
| Callos Andrew | CYTK | EVP, Chief Commercial Officer | May 5 '25 | Sell | $36.68 | 4,002 | $146,793.36 | 60,687 |
Latest Cytokinetics Incorporated News
CYTK Breaking Stock News: Dive into CYTK Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
9 days ago
Cytokinetics, Incorporated (CYTK) Price Target Lowered To $53 from $71 at JPMorgan
Argus Research
11 days ago
CYTK: Raising target price to $36.00
GlobeNewswire
11 days ago
Cytokinetics Announces Call For Proposals For Annual Corporate Giving Program
Zacks
16 days ago
Cytokinetics (CYTK) Down 1.9% Since Last Earnings Report: Can It Rebound?
GlobeNewswire
23 days ago
Cytokinetics to Participate in the Jefferies Global Healthcare Conference
MT Newswires
23 days ago
Mizuho Cuts Price Target on Cytokinetics to $84 From $103, Keeps Outperform Rating
Argus Research
a month ago
CYTK: Rating increased to a HOLD
Compare CYTK vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTK Cytokinetics Incorporated - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.